Skip to main content Skip to section navigation Skip to footer
  • ViraxImmune™
  • Products
  • Services
  • Media
  • Leadership
  • Contact Us
  • Investor Relations
Menu
  • ViraxImmune™
  • Products
  • Services
  • Media
  • Leadership
  • Contact Us
  • Investor Relations
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 16, 2024 8:30am EDT

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Sep 09, 2024 8:00am EDT

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 29, 2024 9:03am EDT

Virax Biolabs to Participate at 7th European Congress of Immunology

Aug 28, 2024 7:30am EDT

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Aug 23, 2024 4:09pm EDT

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024 9:30pm EDT

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 25, 2024 8:00am EDT

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Apr 16, 2024 7:30am EDT

Virax Biolabs to Participate at ESCMID Global 2024

Mar 15, 2024 4:30pm EDT

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Dec 21, 2023 7:30am EST

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

BioCity Glasgow
Bo’Ness Road, Newhouse
Lanarkshire
ML1 5UH
United Kingdom

Quick links

  • ViraxImmune™
  • Products
  • Services
  • Media
  • Leadership
  • Contact Us
  • Investor Relations
  • ViraxImmune™
  • Products
  • Services
  • Media
  • Leadership
  • Contact Us
  • Investor Relations

Follow us

Facebook Twitter Linkedin Instagram
© All Rights Reserved, Virax Biolabs 2024 | Privacy Policy | Terms of Service